Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.03 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance